Evidence map›Paper›PMID 33686651›Full record

ReviewThe Journal of dermatology2021

Rhododendrol-induced leukoderma update I: Clinical findings and treatment.

Kayoko Matsunaga, Kayoko Suzuki, Akiko Ito, Atsushi Tanemura, Yuko Abe, Tamio Suzuki, Momoko Yoshikawa, Yasuyuki Sumikawa, Akiko Yagami, Yukiko Masui and 3 more

Open access · hybridAbstract readReview
In one paragraph

Review in The Journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Review
  4. Targeting Melanin Production: The Safety of Tyrosinase Inhibition.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
  7. Biocompatible exosomes derived fromRegenerative biomaterials · 2025
    Article
  8. Article
  9. Biochemistry and biophysics reports · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Kayoko MatsunagaDepartment of Integrative Medical Science for Allergic Disease, Fujita Health University School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0001-5096-3006
Kayoko SuzukiDepartment of Allergology, Fujita Health University School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0001-8367-1034
Akiko ItoDepartment of Integrative Medical Science for Allergic Disease, Fujita Health University School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0002-6967-0710
Atsushi TanemuraDepartment of Dermatology Course of Integrated Medicine, Osaka University Graduate School of Medicine, Suita, Japan.ORCID https://orcid.org/0000-0002-5239-8474
Yuko AbeDepartment of Dermatology, Faculty of Medicine, Yamagata University, Yamagata, Japan.ORCID https://orcid.org/0000-0002-0903-873X
Tamio SuzukiDepartment of Dermatology, Faculty of Medicine, Yamagata University, Yamagata, Japan.ORCID https://orcid.org/0000-0002-4669-9721
Momoko YoshikawaDepartment of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Yasuyuki SumikawaDepartment of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.ORCID https://orcid.org/0000-0002-8404-1699
Akiko YagamiDepartment of Allergology, Fujita Health University School of Medicine, Nagoya, Japan.
Yukiko MasuiDepartent of Dermatology, Nagata Clinic, Niigata, Japan.ORCID https://orcid.org/0000-0001-7294-9539
Shintaro InoueDepartment of Cosmetic Health Science, Gifu Pharmaceutical University, Gifu, Japan.ORCID https://orcid.org/0000-0002-4996-5693
Shosuke ItoDepartment of Chemistry, Fujita Health University School of Medical Sciences, Toyoake, Japan.ORCID https://orcid.org/0000-0001-9182-5144
Ichiro KatayamaDepartment of Pigmentation Research and Therapeutics, Osaka City University, Osaka, Japan.ORCID https://orcid.org/0000-0002-3270-1085
Fujita Health University · JPSapporo Medical University · JPYamagata University · JPGifu Pharmaceutical University · JPOsaka City University · JPThe University of Osaka · JP

Funding

Kanebo Cosmetics Inc
6 · The paper itself

Abstract

Individuals who used skin-whitening cosmetics (quasi-drugs) containing 2% rhododendrol-containing agents, developed leukoderma at a higher frequency than those who have used other skin-whitening cosmetics. The Rhododenol Research Team (RD-Team) was formed and commissioned by Kanebo Cosmetics Inc. to conduct research in treatments of rhododendrol-induced leukoderma (RDL), to evaluate effective treatment options from a medical standpoint, and provide information to a wide range of people. In this study, we evaluated the efficacy of various treatments for RDL from a medical perspective, based on the information published in the literature as original or review articles. We searched the PubMed (international) and the Igaku Chuo Zasshi (ICHUSHI) (Japanese) databases using the keywords "Rhododenol" and "rhododendrol", for articles published between July 2013 and November 2020. We discuss the main clinical findings and treatments (topical, oral, phototherapy, and surgical) of this condition based on the literature review. We found that ultraviolet light therapy is the most effective treatment for RDL. We have also summarized reports of the efficacy of oral vitamin D3 in RDL. A topical prostaglandin derivative has been reported in a new study to be effective. We have provided guidance for patients using self-tanning and skin-whitening agents to improve their quality of life. Finally, we have highlighted the importance of providing patients with information on contact dermatitis and instructing them to discontinue product use immediately if they develop any symptoms of contact dermatitis while using skin-whitening agents.

Indexed as

HypopigmentationQuality of LifeButanolsHumansMelanocytesButanolsrhododendrolepidemiologymelaninmelanocyteprognosistreatment

Identifiers

PMID33686651
PMCPMC8359339
OpenAlexW3134630801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.